Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTOR™ platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies

Next Previous
X
Search
Trial Profile

A Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTOR™ platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SEL 399 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 08 Nov 2021 According to a Selecta Biosciences media release, the company will be presenting details characterizing the immune response of healthy subjects to empty capsids in a peer-reviewed scientific manuscript and at a major gene therapy conference
    • 08 Nov 2021 Results (n=23) published in Selecta Biosciences Media Release
    • 24 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top